Compare PRPO & PAAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPO | PAAI |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | EDP Services |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.0M | 49.5M |
| IPO Year | 2000 | 2017 |
| Metric | PRPO | PAAI |
|---|---|---|
| Price | $26.25 | $1.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 139.2K | ★ 4.1M |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | 92.15 | ★ 191.93 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,049,000.00 | $16,892,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 29.77 | 27.46 |
| 52 Week Low | $16.14 | $0.87 |
| 52 Week High | $33.63 | $3.47 |
| Indicator | PRPO | PAAI |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 55.66 |
| Support Level | $25.46 | $0.87 |
| Resistance Level | $27.59 | N/A |
| Average True Range (ATR) | 1.66 | 0.56 |
| MACD | -0.30 | 0.11 |
| Stochastic Oscillator | 35.39 | 25.00 |
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.